DRG Market Assessment 보고서

The regulatory and market access landscape for biosimilars is constantly evolving. For a company seeking to develop a biosimilar for multiple markets, keeping track of the similarities and…

Atopic Dermatitis | Emerging Therapies | Eucrisa | USis a three-wave series that tracks the introduction of Pfizer’s Eucrisa for the treatment of AD. The series is based on primary research data…

MARKET OUTLOOK There are multiple well-established therapies available to treat Crohn’s disease (CD). In particular, the mostly widely used biologics, the TNF-α inhibitors (e.g., Janssen/…

The hepatitis B virus (HBV) therapy market is primarily defined by patients chronically infected with HBV who require lifelong treatment with a daily nucleoside analogue. Although the majority of…

As the first agent to be approved for primary biliary cholangitis (PBC), ursodeoxycholic acid (UDCA) was launched nearly two decades ago and transformed the treatment of this disease by…

Heavy menstrual bleeding, pelvic pressure, and infertility are the main clinical manifestations linked to uterine fibroids. Hormonal contraceptives, including coformulated estrogen and progestin…

Pulmonary hypertension (PH), particularly pulmonary arterial hypertension (PAH), is a rare but life-threatening disorder. Commercial interest in PH/PAH has increased recently due to significant…

Myelodysplastic syndromes ( MDS ) is a heterogeneous collection of hematopoietic stem cell disorders that result in cytopenias and risk of progression to acute myeloid leukemia ( AML ). Management…

Amyotrophic lateral sclerosis (ALS) is a degenerative disorder of motor neurons that leads to progressive muscle wasting and weakness, with a typical survival time of three to five years from onset…

Biosimilars│Emerging Biosimilars│Inflectra │U.S. Wave 1 is the first installment of a three-wave, syndicated report series, tracking physician perception and uptake of Pfizer/Celltrion’s…

This three-wave syndicated report series tracks the introduction of Darzalex, a human anti-CD38 MAb, and Empliciti, a humanized anti-SLAMF7 MAb. The FDA approved these agents in November 2015 for…

Following the introduction of the anti-VEGF therapies over a decade ago, the wet AMDmarket has been dominated by three therapies—Roche/Genentech/Novartis’s Lucentis, approved for wet AMD,…